BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GANYMED Pharmaceuticals AG 

Freiligrathstrasse 12

Mainz    D-55131  Germany
Phone: 49-0-6131-1440-10 Fax: 49-0-6131-1440-111


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology

Segment
Pharmaceuticals





 Company News
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014 9:41:23 AM
GANYMED Pharmaceuticals AG's IMAB362 Shows Strong Evidence Of Single-Agent Activity In Phase 2a Trial In Gastroesophageal Cancer 5/27/2014 11:39:08 AM
GANYMED Pharmaceuticals AG's IMAB027 Enters Phase I/II Clinical Trial For Ovarian Cancer 2/12/2014 8:59:37 AM
GANYMED Pharmaceuticals AG To Present At The 32nd Annual J.P. Morgan Healthcare Conference 12/19/2013 9:35:30 AM
GANYMED Pharmaceuticals AG Scrounges Up $60 Million Financing Round 11/18/2013 8:59:58 AM
GANYMED Pharmaceuticals AG's IMAB362 Receives Orphan Drug Designation From FDA and European Medicines Agency for Pancreatic Cancer 10/21/2013 8:58:29 AM
GANYMED Pharmaceuticals AG Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors 9/11/2013 8:17:50 AM
GANYMED Pharmaceuticals AG Release: Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety 8/4/2010 10:57:56 AM
GANYMED Pharmaceuticals AG Closes EUR 65 M Financing Round 11/18/2008 6:29:42 AM
ATS Acquires Majority Shareholding in GANYMED Pharmaceuticals AG 8/21/2008 7:07:06 AM
12